Sponsor:
M.D. Anderson Cancer Center
Code:
NCT06200181
Conditions
Misuse, Opioid
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Olanzapine
Olanzapine
Placebo
Brief summary:
Conditions
Misuse, Opioid
Study ID
NCT06200181
Start date
Apr 2, 2024
Status verified date
May, 2026
Completion date
Nov 1, 2026
Anticipated
Primary completion date
Nov 1, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
87 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Supportive Care
Arms
experimental: Arm 1
experimental: Arm 2
placebo comparator: Arm 3
Interventions
Olanzapine
Olanzapine
Placebo
Primary outcome measure
Central contacts
Locations
MD Anderson Cancer Center
Recruiting
Houston, Texas, United States, 77030
Contacts
Principal Investigator:
Joseph Arthur, MD
Sponsor
M.D. Anderson Cancer Center
Last update posted
Jun 1, 2026
Last verified
May, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-01.